Journal Scans
Defining Prior Therapy in Myelodysplastic Syndromes and Criteria for Relapsed and Refractory Disease: Implications for Clinical Trial Design and Enrollment
MDS Clinical Trial Design in the Era of New Therapy Options
MA Sekeres, DP Steensma
20090824
2009 Sept 24
Blood
Defining Prior Therapy in Myelodysplastic Syndromes and Criteria for Relapsed and Refractory Disease: Implications for Clinical Trial Design and Enrollment
Blood. 2009 Sept 24;114(13):2575-2580, MA Sekeres, DP Steensma
Abstract
Abstract
The recent approval of 3 drugs for the treatment of myelodysplastic syndromes (MDSs) has resulted in a revolution in therapeutic options that was absent a decade ago. At the same time, the changing MDS environment is raising new challenges in clinical trial design and defining new indications for MDS drugs. Many current trials still rely on IPSS-based enrollment criteria, despite the well-recognized limitations of the IPSS. Clinical trialists designing studies struggle with several important trial...
